COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of ...

Standard Health is a clinical healthcare provider, responsible for site development and operation of the facility with Smith+Nephew supplying its innovative portfolio of medical technologies. Standard ...

La stéatose hépatique est fréquente chez les patients diabétiques de type 2, révèle cette équipe d’endocrinologues de ...

Larry Nichols, Chief Executive Officer of Steri-Tek, commented: " The integration of IBA's Be Wide X-ray Solution into our newest facility is a transformative step, enhancing our ability to serve ...

Larry Nichols, Chief Executive Officer de Steri-Tek, a commenté : « L'intégration de la solution à rayons X Be Wide d'IBA dans notre dernier centre de stérilisation est une étape stratégique. Elle va ...

All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Biomea. The gross proceeds to Biomea from the offering, before deducting underwriting ...

The 113th Congress of Japan Society of Aesthetic Surgery Venue：The Okura Tokyo Dates：Wednesday, May 28 – Friday, May 30, 2025 ...

This press release has been updated to reflect the correct timing of the funding round. Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its ...

(NASDAQ: EYEN) (“Eyenovia” or the “Company”) today announced that it has entered into a securities purchase agreement (the “SPA”) for a $50 million private placement in public equity (the “PIPE ...

NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- WW International, Inc., the global leader in science-backed weight management (“WeightWatchers” or the “Company”), today announced that, following approval ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Pursuant to section 32 of the Danish Capital Markets Act No. 652 of June 10, 2025, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK ...